Associations - Neurofibrosarcoma

NTRK1 fusion NTRK1 fusion	Neurofibrosarcoma Neurofibrosarcoma	NTRK1 fusion NTRK1 fusion	Neurofibrosarcoma Neurofibrosarcoma	entrectinib Sensitive: C1 - Off-label	entrectinib Sensitive: C1 - Off-label
NTRK3 fusion NTRK3 fusion	Neurofibrosarcoma Neurofibrosarcoma	NTRK3 fusion NTRK3 fusion	Neurofibrosarcoma Neurofibrosarcoma	entrectinib Sensitive: C1 - Off-label	entrectinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Neurofibrosarcoma Neurofibrosarcoma	BRAF V600E BRAF V600E	Neurofibrosarcoma Neurofibrosarcoma	vemurafenib Sensitive: C1 - Off-label	vemurafenib Sensitive: C1 - Off-label
NF2 E108X NF2 E108X	Neurofibrosarcoma Neurofibrosarcoma	NF2 E108X NF2 E108X	Neurofibrosarcoma Neurofibrosarcoma	everolimus Resistant: C3 – Early Trials	everolimus Resistant: C3 – Early Trials
NF2 E108X NF2 E108X	Neurofibrosarcoma Neurofibrosarcoma	NF2 E108X NF2 E108X	Neurofibrosarcoma Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials	temsirolimus Sensitive: C3 – Early Trials
TSC2 A736V TSC2 A736V	Neurofibrosarcoma Neurofibrosarcoma	TSC2 A736V TSC2 A736V	Neurofibrosarcoma Neurofibrosarcoma	everolimus Resistant: C3 – Early Trials	everolimus Resistant: C3 – Early Trials
TSC2 A736V TSC2 A736V	Neurofibrosarcoma Neurofibrosarcoma	TSC2 A736V TSC2 A736V	Neurofibrosarcoma Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials	temsirolimus Sensitive: C3 – Early Trials
TJP1-ROS1 fusion + NF1 mutation TJP1-ROS1 fusion + NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	TJP1-ROS1 fusion + NF1 mutation TJP1-ROS1 fusion + NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	crizotinib Resistant: C4 – Case Studies	crizotinib Resistant: C4 – Case Studies
NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	DR6MP + JHU395 Sensitive: D – Preclinical	DR6MP + JHU395 Sensitive: D – Preclinical
NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	DR6MP Sensitive: D – Preclinical	DR6MP Sensitive: D – Preclinical
NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	NF1 mutation NF1 mutation	Neurofibrosarcoma Neurofibrosarcoma	MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical	MEK inhibitor + c-MET inhibitor Sensitive: D – Preclinical
TP53 mutation TP53 mutation	Neurofibrosarcoma Neurofibrosarcoma	TP53 mutation TP53 mutation	Neurofibrosarcoma Neurofibrosarcoma	AZD1775 Sensitive: D – Preclinical	AZD1775 Sensitive: D – Preclinical

Neurofibrosarcoma

Associations(12)

Associations
(12)